Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation

Απλή σελίδα τεκμηρίου
dc.contributor.authorChristodoulou, C.en
dc.contributor.authorKostopoulos, I.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorLianos, E.en
dc.contributor.authorBobos, M.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorGogas, H.en
dc.contributor.authorRazis, E.en
dc.contributor.authorSkarlos, D. V.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T19:09:10Z
dc.date.available2015-11-24T19:09:10Z
dc.identifier.issn1423-0232-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20665
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntibodies, Monoclonal/*administration & dosage/adverse effectsen
dc.subjectAntibodies, Monoclonal, Humanizeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectBreast Neoplasms/chemistry/*drug therapy/mortalityen
dc.subjectDoxorubicin/administration & dosage/adverse effects/*analogs & derivativesen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectPTEN Phosphohydrolase/analysisen
dc.subjectPolyethylene Glycols/*administration & dosage/adverse effectsen
dc.subjectProtein Kinases/analysisen
dc.subjectReceptor, erbB-2/analysisen
dc.subjectTOR Serine-Threonine Kinasesen
dc.subjectVentricular Function, Left/drug effectsen
dc.titleTrastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluationen
heal.abstractOBJECTIVE: Combination of trastuzumab and anthracyclines in metastatic breast cancer (MBC) is precluded due to cardiotoxicity. Pegylated liposomal doxorubicin (PLD) is the least cardiotoxic among the anthracyclines. We performed a phase II study of trastuzumab and PLD with biomarker evaluation. METHODS: Patients with MBC and HER2 overexpression, assessed as 3+ at local laboratories, received trastuzumab 8 mg/kg as loading dose followed by 6 mg/kg in combination with PLD 30 mg/m(2), both given every 3 weeks. To be eligible, patients should have received first-line chemotherapy for MBC or should have relapsed within a year of adjuvant taxane. Tumor tissue blocks were collected for central review and exploratory biomarker evaluation. Left-ventricular ejection fraction (LVEF) was closely monitored by cardiac ultrasound. RESULTS: Among 37 patients, an overall response rate of 22% was observed with a progression-free survival (PFS) of 6.5 months (0.8-31.1, 95% CI 2.7-10.3) and a survival of 18.7 months (1.6-40.8, 95% CI 3.7-33.7). No decline in LVEF was noticed. Overexpression of mTOR and TOP2A gene alterations were associated with better PFS. PTEN gene deletion was associated with resistance to treatment. CONCLUSION: Trastuzumab combined with PLD every 3 weeks is feasible, effective and safe in HER2-positive patients.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1159/000207504-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/19262067-
heal.identifier.secondaryhttp://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000207504-
heal.journalNameOncologyen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2009-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ